IDX184 is a liver-targeted prodrug of the nucleotide 2′-MeG-MP. IDX184 is a liver-targeted nucleotide polymerase inhibitor of hepatitis C virus[1].
IDX184 is a second generation, orally bioavailable nucleotide prodrug designed to provide increased anti-HCV efficacy and safety versus the parent nucleoside. In HCV replicon testing, IDX184 is the most potent inhibitor (EC50=0.3-0.45 μM) compared to any of the 2’ or 4’ modified nucleosides (EC50=4-6 μM) and is also highly inhibitory in the JFH-1 infectious system (EC50=0.06-0.11 μM). IDX184 is not toxic (CC50>100μM) in any tested cell line[2].
References:
[1]. Xiao-Jian Zhou , et al. Safety and Pharmacokinetics of IDX184, a Liver-Targeted Nucleotide Polymerase Inhibitor of Hepatitis C Virus, in Healthy Subjects. Antimicrob Agents Chemother. 2011 Jan;55(1):76-81.
[2]. IN VITRO ANTIVIRAL ACTIVITY AND PHARMACOLOGY OF IDX184, A NOVEL AND POTENT INHIBITOR OF HCV REPLICATION.